Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH supports echinacea research

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health says May 6 it will give $4.4 mil. in continuation funding to an Iowa State University research center dedicated to understanding and improving echinacea and hypericum perforatum (St. John's wort). The Iowa Center for Research on Botanical Dietary Supplements will study the plants' bioavailability for three years, "focusing on cellular, signaling, pathways and receptors," it says. Additionally, researchers will study prunella, known to treat ailments such as inflammatory bowel disease, fever, headache and diarrhea. The center was created in 2002 by NIH's Office of Dietary Supplements (1"The Tan Sheet" July 29, 2002, p. 10)...

You may also be interested in...



Iowa Botanical Center To Study Echinacea, Hypericum Bioactive Constituents

A botanical research center at Iowa State University will focus on identifying the bioactive constituents in echinacea and hypericum (St. John's wort)

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel